Senate committee advances nomination of Dr. Erica Schwartz to be Trump’s…

A Senate committee on Thursday advanced Dr. Erica Schwartz’s nomination to be director of the Centers for Disease Control and Prevention, overcoming concerns that she might not resist political pressure from President Donald Trump’s health secretary, Robert F. Kennedy Jr. The vote marks a pivotal step toward her confirmation, though it has sparked debate over her ability to safeguard the agency’s scientific integrity amid a broader crisis of leadership and morale at the CDC.

Schwartz, a 54-year-old physician with medical and law degrees, faces scrutiny over her responses during a contentious hearing in which senators questioned whether she would defy political appointees who prioritize ideology over public health. Sen. Bill Cassidy, R-La., the chairman of the Senate Health, Education, Labor and Pensions Committee, initially expressed doubts after the hearing but later endorsed her, citing assurances that she would “stand against those who do not” align with scientific principles. His support was critical to the nomination’s advancement, which passed in a near-party-line vote.

Opposition came from Sen. Bernie Sanders, I-Vt., who argued that the Trump administration’s track record on science and public health — marked by Kennedy’s controversial efforts to revise vaccine recommendations — raises doubts about Schwartz’s independence. “Will we have people in the Trump administration who have the guts to stand up to people who are anti-science and into conspiracy theories?” Sanders asked, echoing broader concerns about the agency’s direction.

The CDC has been in turmoil since Trump returned to office, with over 3,000 employees leaving, more than a quarter of its workforce, due to layoffs, resignations, and a revolving door of temporary leaders. The agency’s leadership vacuum has left it vulnerable to political influence, with Kennedy’s tenure as health secretary drawing sharp criticism for prioritizing ideological goals over evidence-based policies. Schwartz’s nomination has been seen as a test of whether the administration can stabilize the agency, though public health advocates remain skeptical.

During her hearing, Schwartz pledged to “never betray the science” but avoided committing to specific actions if pressured by political figures. She also declined to criticize a CDC website that previously suggested a link between vaccines and autism, a stance that drew criticism from the National Public Health Coalition. The group urged senators to demand written assurances that Schwartz would prioritize scientific independence, arguing that her responses were “incomplete, vague, or missing.”

Despite these concerns, some experts view Schwartz as a potential stabilizing force. Dr. Georges Benjamin of the American Public Health Association noted her qualifications and potential to rebuild the CDC’s fractured command structure. Dr. Daniel Jernigan, a former CDC official, warned that without her confirmation, the agency would remain “rudderless,” allowing Kennedy to continue his “anti-science and anti-vaccine efforts.”

The nomination comes amid a series of high-stakes confirmations in Trump’s administration, including the approval of Sean Kaufman to lead the agency overseeing pandemic preparedness. Kaufman, whose past statements have drawn criticism from public health advocates, was also advanced by the Senate committee, highlighting the administration’s broader pattern of appointing figures with controversial views on vaccines and public health policy.

Schwartz’s confirmation would make her the 22nd CDC director, following a string of interim leaders. Her nomination has been shaped by the administration’s struggle to balance political priorities with the agency’s public health mission, a tension that has defined its leadership since Trump’s return to power. As the full Senate prepares to vote, the outcome will signal whether the administration can restore credibility to an agency central to protecting American health.